Researchers at the CSIR Centre for Cellular and Molecular Biology in Hyderabad, working with the Translational Health Science and Technology Institute, have identified two small molecules that prevent Candida albicans from switching into the thread-like form it uses to invade tissue — without killing the fungus. The compounds target glycolysis, the cell’s sugar-processing pathway, and specifically the enzyme pyruvate kinase. In laboratory work they cut biofilm formation by roughly three-quarters, made the fungus more vulnerable to two standard antifungals, and improved survival in infected mice. The approach matters because killing a pathogen selects for resistance, and merely disarming it may not.
Candida albicans lives harmlessly in the gut, mouth and on the skin of a large fraction of healthy people. It becomes dangerous when it changes shape. In its yeast form it is a round, budding single cell. Under certain conditions it elongates into filaments — hyphae and pseudohyphae — that penetrate tissue, form drug-resistant mats called biofilms on catheters and implants, and allow the organism to spread into the bloodstream. Invasive candidiasis is lethal in a substantial proportion of cases, and the World Health Organization has placed C. albicans in the critical-priority group of its fungal pathogen list.
The number of antifungal drug classes available to clinicians is very small — far smaller than the antibacterial armoury — and resistance to them is rising. That scarcity is why a different kind of target is interesting.
What the Hyderabad group did
The work comes from the laboratory of Dr Sriram Varahan at CSIR-CCMB, with collaborators at BRIC-THSTI, the Translational Health Science and Technology Institute in Faridabad. The first author is Dhrumi Shah, with affiliations given as CCMB, the Academy of Scientific and Innovative Research and THSTI.
The group’s starting point was metabolic rather than pharmacological. The switch from yeast to filament is an expensive change for a cell to make, and the team’s premise was that glycolysis — the pathway that breaks down glucose to pyruvate and supplies both energy and carbon skeletons — functions as the gate controlling it. If glycolysis is the gate, then inhibiting a glycolytic enzyme should hold the fungus in its harmless round form.
They screened 112 compounds known to target glycolytic enzymes. Two emerged: NPD10084 and PKM2-IN-6, both inhibitors of pyruvate kinase, the enzyme that catalyses the final step of glycolysis.
The reported results, taken from the group’s preprint, are:
- Both compounds blocked the yeast-to-filament switch.
- Biofilm formation was reduced by about 77 per cent.
- One compound increased the fungus’s sensitivity to fluconazole and amphotericin B, the two mainstays of antifungal therapy.
- Treatment improved survival in mice with systemic infection.
Why anti-virulence is a different strategy
Conventional antimicrobials kill, and killing imposes the strongest possible selection pressure: any variant that survives inherits the whole population. This is the mechanism by which resistance emerges, and it operates on antifungals exactly as it does on antibiotics.
An anti-virulence compound works differently in principle. If a molecule does not kill the fungus but only prevents it from adopting its invasive form, the selective advantage conferred by resistance to that molecule is weaker, because a non-resistant organism is not eliminated — it simply remains commensal. The theoretical consequence is slower evolution of resistance.
NSH notes that this is an argument from principle, widely discussed in the field, and not something this study demonstrates. No resistance-evolution experiment is reported. The claim that anti-virulence approaches generate resistance more slowly remains a hypothesis in need of its own evidence.
The second reported finding is arguably the more immediately useful one. If blocking pyruvate kinase makes C. albicans more susceptible to fluconazole and amphotericin B, then the compounds could function as adjuvants — given alongside existing antifungals to make lower doses effective, or to restore the effectiveness of a drug the strain has become partially resistant to. Adjuvant strategies have a clearer route to the clinic than wholly new agents, because the partner drug is already approved.
What is not yet established
Three limitations are substantial, and NSH states them rather than burying them.
First, the journal citation cannot be confirmed. News reports describe the work as published in ACS Infectious Diseases. NSH searched the publisher’s site, PubMed and PubMed Central, including by exact title, and could not locate the paper, a DOI or a publication date. The compound names, mechanism and effect sizes reported above are therefore taken from the group’s bioRxiv preprint, which NSH read, and not from a peer-reviewed version of record. NSH flags that the preprint exists in two versions which differ on one set of findings. Readers and editors should treat the figures as preprint figures until the journal record appears.
Second, this is preclinical work. The mouse survival experiment used six animals, which is a small group even by the standards of early animal studies, and the evidence that the compounds bind pyruvate kinase at the proposed site is computational modelling rather than structural biology. Neither compound is an approved medicine, and neither has been through toxicology in humans.
Third, inhibiting a core metabolic enzyme raises an obvious safety question. Pyruvate kinase is not a fungus-specific enzyme; human cells run glycolysis too, and PKM2 is a human pyruvate kinase isoform that has been studied extensively as a cancer target. Whether a compound can inhibit the fungal enzyme sufficiently without disturbing host metabolism is precisely the question that preclinical development exists to answer, and it is unanswered here.
The context in which it lands
The work was reported as World AMR Awareness Week opened on 18 November, under the WHO theme “One Health, one action: Prevent AMR now”, and in the same window as the Indian Council of Medical Research’s surveillance report documenting severe resistance in Indian hospitals — including the finding that Candida species are among the commonest organisms in bloodstream infections in newborns.
That juxtaposition is the reason this item deserves attention beyond its novelty. India has a documented, measured problem with resistant hospital-acquired infection, including fungal infection in its most vulnerable patients, and the research response is coming from Indian public laboratories. CCMB is a CSIR institute; THSTI is a Department of Biotechnology institute. This is publicly funded Indian science working on a problem Indian hospitals are measuring.
The distance from a screened compound to a usable drug remains long — typically a decade or more, with high attrition — and most compounds that look promising at this stage do not arrive. That is the normal shape of drug discovery and not a criticism of the work.
– Rashmi M



